Over 500 medical professionals attended the 2nd World Congress on Ga68 and Radiotherapy that was held in Chandigarh India, February 28 - March 2, 2013.  Over the course of 3 days over 100 presentations and posters were presented reflecting the current usage of Ga68 and PRRT around the world as well as new and exciting development that have taken place since the 1st world congress in 2011.  The abstracts for this conference as well as for the 22nd Singapore Nuclear Review are available

Read more: Presentations from the 2nd World Congress on Ga68

The results from the first randomized control trial of PRRT were released today in Vienna, Austria showing increased progression free survival compared to high dose octreotide LAR.

PRRT while available in many parts of the world has not yet been approved for use pending prospective randomized clinical trails (RCT). Having a positive RCT for PRRT will greatly expand access and availability to PRRT around the world. Click here to download the full release.

AAA Opens Lutathera Expanded Access Program In U.S. to Eligible Patients And Announces Forthcoming NDA Filing to FDA and EMA.

AAA today announced that the company has initiated an expanded access program (EAP) in the United States for the investigational product, Lutathera. Through the program, Lutathera is being made available for patients suffering from inoperable, somatostatin receptor positive, midgut carcinoid tumors, progressive under somatostatin analogue therapy. Healthcare

Read more: Lutathera Expanded Access Program In U.S.

While we were in Chandigarh, India for the 2nd World Congress on Ga68 we were abole to film the following press conference with Professors Baum, Shultz and Singh about the importance of the Congress. Please make sure to click the read more button to see all 3 talks.

Read more: Press Conference 2WC on Ga68 and PRRNT

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours (NETTER-1) is now open in the US and Europe and is actively recruiting patients.

The study is seeking 200 patients at over 50 institutions in a randomized trial - those that are randomized to the non-PRRT arm will receive LAR 60 (high dose).

To learn more about the trial, please visit clinicaltrials.gov.

At the 2nd Theranostics World Congress there was progress towards the treatment of metastatic prostate cancer using a Theranostics approach. At the 3rd Theranostics World Congress that progress continued from the bench and to the bedside.

This video is an overview of the treatment and management of metastatic prostate cancer using a Theranostic Approach.